-

Bayer Corn Trait Gains EPA Approval: VT4PRO™ with RNAi Technology to Launch in US as Early as 2024

Versatile product will provide broad geographic fit and the widest spectrum of insect defense from Bayer

ST. LOUIS--(BUSINESS WIRE)--Bayer announced today the commercial registrations from the EPA for the traits that will enable the commercialization of its newest corn product, VT4PRO™ with RNAi Technology, in the United States. VT4PRO™ Technology* will provide US farmers an additional option within the already-strong Bayer corn product portfolio to help control troublesome above-ground and below ground pests.

VT4PRO™ Technology will mark the first product that combines the power of the three modes of built-in action in Trecepta® Technology, an elite above-ground pest package for corn that controls insects such as corn earworm and western bean cutworm, along with an RNAi-based mode of action, the latest defense to help manage corn rootworm.

“We’re excited about the potential of this product and believe it will provide tremendous value for farmers, helping provide added protection against some of the toughest corn pests,” said Scott Stein, North America Corn Product Management Lead. “The addition of VT4PRO™ Technology to our portfolio gives farmers another choice in Bayer’s already-robust product lineup. We anticipate that this offering will have a broad geographic fit and will provide corn growers the widest spectrum of insect defense from Bayer.”

A complement to Bayer’s existing portfolio, VT4PRO™ Technology will complement other products like SmartStax® PRO Technology and offer an additional option for growers looking for products that will perform well in low-to-moderate corn rootworm pressure conditions, along with potential higher risk for corn earworm or western bean cutworm.

“This product is another example of Bayer’s commitment to developing and delivering innovative products for farmers through our corn product pipeline,” said Stein. “With an annual investment of more than $2 billon, we’re dedicated to developing technology that provides innovative solutions that help growers address the tough challenges they face on their farms.”

Bayer plans to conduct large scale field testing of VT4PRO™ Technology during the 2022 and 2023 growing seasons with the potential to launch commercial volumes as early as 2024, pending state registrations.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2020, the Group employed around 100,000 people and had sales of 41.4 billion euros. R&D expenses before special items amounted to 4.9 billion euros. For more information, go to www.bayer.com.

*VT4PRO™ with RNAi Technology is not currently available for commercially sale or planting. ALWAYS READ AND FOLLOW IRM, WHERE APPLICABLE, GRAIN MARKETING AND ALL OTHER STEWARDSHIP PRACTICES AND PESTICIDE LABEL DIRECTIONS. ©2022 Bayer Group. All rights reserved.

Contacts

Bayer - Brian Leake 314.370.3285
Brian.Leake@Bayer.com

Bayer


Release Versions

Contacts

Bayer - Brian Leake 314.370.3285
Brian.Leake@Bayer.com

More News From Bayer

Bayer to Invest 2.2 Billion U.S. Dollars in a New Manufacturing Site in the United States

NEW ALBANY, Ohio--(BUSINESS WIRE)--Bayer announced on Friday plans to invest 2.2 billion U.S. dollars in a new pharmaceutical manufacturing site in New Albany, Ohio, U.S. Building on more than seven billion dollars in U.S. pharma R&D and manufacturing spend over the past five years, the project is a central element of Bayer’s long-term growth strategy and commitment to innovation and patient access in its largest pharmaceuticals market. “Bayer has long seen the United States as a key manufa...

Alka-Seltzer Plus® to Relaunch as Alka-Seltzer™ Cold in 2026, Bringing Simpler Shopping and More Value to the Cough/Cold Aisle

WHIPPANY, N.J.--(BUSINESS WIRE)--Alka-Seltzer Plus® will relaunch in 2026 as Alka-Seltzer™ Cold, introducing a more intuitive brand architecture, simplified packaging and value-focused options designed to make the cough/cold aisle easier to shop. The relaunch reflects a sharper focus on the moments when consumers are sick, pressed for time and looking for trusted solutions that are easy to understand and accessible at the shelf. Key facts at a glance - New brand name: Alka-Seltzer™ Cold, replac...

MiraSOFT™ Launch at CVS Pharmacy, Expanding the MIRA Portfolio with a Stool Softener Option

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced the launch of MiraSOFT, a new stool softener option from the makers of MiraLAX® with the active ingredient docusate sodium designed to help gently soften hard, dry stools and support more comfortable, easier bowel movements. * MiraSOFT is now available at over 7,000 CVS Pharmacy locations and at cvs.com. Availability and where to find MiraSOFT at CVS Pharmacy: Retail footprint: Over 7,000 CVS Pharmacy stores and cvs.com In-store location: D...
Back to Newsroom